Related Experiment Video
Updated: Feb 10, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
Transcriptome based individualized therapy of refractory pediatric sarcomas: feasibility, tolerability and efficacy
Bushra Weidenbusch1, Günther H S Richter1,2, Marie Sophie Kesper1,2
1Department of Pediatrics and Children's Cancer Research Center, Kinderklinik München Schwabing, Klinikum rechts der Isar, Fakultät für Medizin, Technische Universität München, Munich, Germany.
Abstract:
Survival rates of pediatric sarcoma patients stagnated during the last two decades, especially in adolescents and young adults (AYAs). Targeted therapies offer new options in refractory cases. Gene expression profiling provides a robust method to characterize the transcriptome of each patient's tumor and guide the choice of therapy. Twenty patients with refractory pediatric sarcomas (age 8-35 years) were assessed with array profiling: ten had Ewing sarcoma, five osteosarcoma, and five soft tissue sarcoma. Overexpressed genes and deregulated pathways were identified as actionable targets and an individualized combination of targeted therapies was recommended. Disease status, survival, adverse events (AEs), and quality of life (QOL) were assessed in patients receiving targeted therapy (TT) and compared to patients without targeted therapy (non TT). Actionable targets were identified in all analyzed biopsies. Targeted therapy was administered in nine patients, while eleven received no targeted therapy. No significant difference in risk factors between these two groups was detected. Overall survival (OS) and progression free survival (PFS) were significantly higher in the TT group (OS: P=0.0014, PFS: P=0.0011). Median OS was 8.83 versus 4.93 months and median PFS was 6.17 versus 1.6 months in TT versus non TT group, respectively. QOL did not differ at baseline as well as at four week intervals between the two groups. TT patients had less grade 1 AEs (P=0.009). The frequency of grade 2-4 AEs did not differ. Overall, expression based targeted therapy is a feasible and likely beneficial approach in patients with refractory pediatric sarcomas that warrants further study.
Insights
Gene expression profiling identified actionable targets in pediatric sarcomas. Targeted therapy significantly improved overall survival and progression-free survival in refractory cases, showing promise for future treatment strategies.
Area of Science:
- Pediatric Oncology
- Molecular Diagnostics
- Cancer Therapeutics
Background:
- Pediatric sarcoma survival rates have plateaued, particularly for adolescents and young adults (AYAs).
- Refractory cases require novel treatment strategies beyond conventional therapies.
- Gene expression profiling offers a method to characterize tumor transcriptomes and guide personalized treatment.
Purpose of the Study:
- To assess the feasibility and efficacy of expression-based targeted therapy (TT) in pediatric sarcoma patients.
- To identify actionable molecular targets in refractory pediatric sarcomas using gene expression profiling.
- To compare outcomes, including survival and adverse events, between patients receiving TT and those not.
Main Methods:
- Array-based gene expression profiling was performed on tumor biopsies from 20 pediatric sarcoma patients (ages 8-35).
- Actionable targets and deregulated pathways were identified to guide individualized TT selection.
- Patients receiving TT were compared to a control group (non TT) regarding disease status, survival, adverse events (AEs), and quality of life (QOL).
Main Results:
- Actionable targets were identified in all analyzed pediatric sarcoma biopsies.
- Nine patients received TT, while eleven did not; no significant differences in risk factors were observed between groups.
- TT significantly improved overall survival (OS) and progression-free survival (PFS) compared to non TT (median OS: 8.83 vs. 4.93 months; median PFS: 6.17 vs. 1.6 months).
- Quality of life (QOL) did not differ between groups. TT patients experienced fewer grade 1 AEs, with no difference in grade 2-4 AEs.
Conclusions:
- Expression-based targeted therapy is a feasible approach for refractory pediatric sarcomas.
- Targeted therapy demonstrated significant survival benefits in this patient cohort.
- Further investigation is warranted to confirm the efficacy and benefits of targeted therapy in pediatric sarcoma treatment.
Related Concept Videos
Self-Efficacy
Impact of Individuals on Individuals
Gene Therapy
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Impact of Groups on Individuals
Impact of Individuals on a Group

